Skip to main content
. 2020 Jun 25;21(12):4534. doi: 10.3390/ijms21124534

Figure 1.

Figure 1

Effects of SGL 121(ginsenoside F2-enhanced mixture) on body weight and fat mass in nonalcoholic fatty liver disease (NAFLD)-induced mice. (A) Bodyweight changes, (B) bodyweight at week 12, (C) dual-energy X-ray absorptiometry (DXA) image of fat distribution, and (D) fat mass. Data are presented as the mean ± SE, n = 8. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the high-fat, high-carbohydrate (HFHC) group.